Pages that link to "Q40758193"
Jump to navigation
Jump to search
The following pages link to Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling (Q40758193):
Displaying 50 items.
- Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model (Q21133610) (← links)
- Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma (Q24607424) (← links)
- Cixutumumab (Q24609058) (← links)
- Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells (Q24810622) (← links)
- Cancer Stem Cell Hierarchy in Glioblastoma Multiforme (Q26752312) (← links)
- Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization (Q26771165) (← links)
- Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer (Q26852215) (← links)
- Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies (Q26852366) (← links)
- Molecular biology of gliomas: present and future challenges (Q27001295) (← links)
- The insulin-like growth factor system in cancer (Q27013945) (← links)
- Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer (Q27852235) (← links)
- Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives (Q28071388) (← links)
- Epidermal growth factor signaling in transformed cells (Q28084034) (← links)
- Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments (Q28547357) (← links)
- Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells (Q28729071) (← links)
- A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations (Q29614275) (← links)
- Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease (Q30315828) (← links)
- Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells (Q30424348) (← links)
- Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors (Q30438487) (← links)
- Bayesian methods for expression-based integration of various types of genomics data. (Q30668548) (← links)
- A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor (Q30992402) (← links)
- Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotini (Q33416585) (← links)
- Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN. (Q33576476) (← links)
- Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence (Q33664297) (← links)
- A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties (Q33846405) (← links)
- Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma (Q33875560) (← links)
- Role of receptor tyrosine kinases and their ligands in glioblastoma (Q33883849) (← links)
- Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach (Q33925323) (← links)
- Understanding resistance to EGFR inhibitors-impact on future treatment strategies (Q34088424) (← links)
- Defining the pathway to insulin-like growth factor system targeting in cancer (Q34107722) (← links)
- Dissecting variability in responses to cancer chemotherapy through systems pharmacology (Q34139962) (← links)
- Targeted Therapies for Thymic Malignancies (Q34149286) (← links)
- Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients (Q34316522) (← links)
- Can we unlock the potential of IGF-1R inhibition in cancer therapy? (Q34336988) (← links)
- RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients (Q34349820) (← links)
- Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell lines (Q34406479) (← links)
- Dual inhibition of epidermal growth factor receptor and insulin‐like growth factor receptor I: Reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma (Q34442002) (← links)
- Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. (Q34569071) (← links)
- Combination of Anti-IGF-1R Antibody A12 and Ionizing Radiation in Upper Respiratory Tract Cancers (Q34612359) (← links)
- Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas (Q34675581) (← links)
- Deficiency of insulin-like growth factor-1 receptor confers resistance to oxidative stress in C2C12 myoblasts (Q34723062) (← links)
- TWIST is expressed in human gliomas and promotes invasion (Q34769731) (← links)
- Network signatures of survival in glioblastoma multiforme (Q34998178) (← links)
- Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials (Q35006620) (← links)
- Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer (Q35076220) (← links)
- Applications of Molecular Imaging (Q35082412) (← links)
- Receptor-Tyrosine-Kinase-Targeted Therapies for Head and Neck Cancer (Q35102025) (← links)
- Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors (Q35116206) (← links)
- Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma. (Q35143738) (← links)
- Innovative Therapies against Human Glioblastoma Multiforme (Q35374492) (← links)